Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations

"....The present study strengthens the known links between BRCA2 and pancreatic and prostate cancer, but throws further doubt onto any association with BRCA1.

New associations with upper gastro-intestinal malignancy need to be treated with caution and confirmed by large prospective studies"

The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas

Objective.

To assess the morbidity and mortality associated with extensive upper abdominal surgery (EUAS) performed during primary cytoreduction for advanced ovarian carcinoma.

abstract: Hormone prevention strategies for breast, endometrial and ovarian cancers

"Prospective, randomized trials, designed to control for all known variables, are mandatory to fully assess the potential for hormonal chemoprevention in breast, endometrial and ovarian cancers."

abstract: Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing — PNAS

Abstract:
"Inherited loss-of-function mutations in the tumor suppressor genes BRCA1, BRCA2, and multiple other genes predispose to high risks of breast and/or ovarian cancer. Cancer-associated inherited mutations in these genes are collectively quite common, but individually rare or even private. Genetic testing for BRCA1 and BRCA2 mutations has become an integral part of clinical practice, but testing is generally limited to these two genes and to women with severe family histories of breast or ovarian cancer.
To determine whether massively parallel, “next-generation” sequencing would enable accurate, thorough, and cost-effective identification of inherited mutations for breast and ovarian cancer, we developed a genomic assay to capture, sequence, and detect all mutations in 21 genes, including BRCA1 and BRCA2, with inherited mutations that predispose to breast or ovarian cancer"
"There were zero false-positive calls of nonsense mutations, frameshift mutations, or genomic rearrangements for any gene in any of the test samples. This approach enables widespread genetic testing and personalized risk assessment for breast and ovarian cancer"

support group meetings - feel free to share - OCATS June 7th

OCATS Ovarian Cancer Awareness & Treatment in Saskatchewan ------------------------------------------------------------------------------------- GYNECOLOGIC CANCER SURVIVORS & SUPPORT PEOPLE WELCOME MONDAY, June 7th 4:00 p.m. to 6:00 p.m. Knox Met United Church 2340 Victoria Avenue (Pls Use Vic Ave Entrance, Ring Buzzer for Room 105) Light Supper, $4 Donation This month our peer support gathering will have our regular check in, and then a facilitated discussion about the challenges and coping strategies for socializing and traveling after diagnosis, while having treatment, during recovery. We don’t have the answers exactly but we’ll share some of the experiences we’ve had for air travel, car travel, hotels, family holidays, special events and share how people have coped and what things they found were useful and helpful or things to avoid. Please come share in the discussion, meet other cancer survivors. It’s good to get out once in awhile and share with others, learn from others. It’s even okay to be grumpy about it! If that’s where you’re at. Please call Darlene at 775-1848 or email and let us know if you plan to attend. This helps Joan prepare those lovely meals she making for us! Thank you, Darlene Gray OCATS Ovarian Cancer Awareness & Treatment in Saskatchewan A SUPPORT & ACTION GROUP FOR ANYONE AFFECTED BY GYNECOLOGIC CANCERS RPO Box 35067, Regina, SK S4X 4C6 Ph 306-775-1848, Fx 306-775-1853 Find us on Facebook too! http://www.ocats.ca

Genetic/Familial High-Risk Assessment: Breast and Ovarian — J Natl Compr Canc Network NCCN

Note: full free access; includes risks of Li-Fraumeni, Cowden and Lynch Syndromes

Teal Toes: Women’s Health Week, Ovarian Cancer media/video - link between breast/ovarian cancers

Note: no mention of other genetic risks aside from the BRCA's

abstract: The inherited genetics of ovarian and endometrial cancer

"Endometrial and epithelial ovarian cancers are the fourth and fifth most common cancers in women in developed countries, after breast, lung, and colorectal cancer. In the United States alone, in 2008 there were about 40000 new diagnoses of endometrial cancer and 7500 disease-related deaths. For ovarian cancer, there were about 22000 new diagnoses and 15000 deaths over the same period. The purpose of this article is to review the recent developments in the inherited genetics of ovarian and endometrial cancer, with particular attention to recent progress in identifying common low-penetrance susceptibility genes and their clinical implications."

Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype

Note: see abstract for further information

Results:
Seventy-nine patients with EOC/PPC and germline BRCA1/2 mutations were identified. Fifteen had inadequate clinical data, two had carcinosarcoma, 27 had previous breast cancer, and 16 were in remission. Of the remaining 19 patients who were BRCA1/2 deficient, 14 patients (74%) developed visceral metastases compared with six (16%) of 38 patients in the control group. The percentages of liver, lung, and splenic metastases were 53%, 32%, and 32%, respectively, in the patients compared with 5%, 3%, and 5%, respectively, in the controls.
Conclusion:
Although sporadic EOC commonly remains confined to the peritoneum, BRCA1/2-deficient ovarian cancer frequently metastasizes to viscera. These data extend the ovarian BRCAness phenotype, imply BRCA1/2-deficient ovarian cancer is biologically distinct, and suggest that patients with visceral metastases should be considered for BRCA1/2 sequencing.

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? (Avastin)

Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms

"Endometrial and ovarian carcinomas with undifferentiated components have a broad histologic differential diagnosis, but they show specific histologic features that should enable accurate diagnosis. These tumors can occur in young women, may be associated with microsatellite instability and behave in a clinically aggressive manner." Modern Pathology

HE4: a new potential early biomarker for the recurrent ovarian cancer

"The follow-up study showed an increase of HE4 5-8 months before CA125 increment in five of the eight patients, this early expression being strictly associated to a relapse of the disease. In conclusion, this study showed that HE4, compared to CA125, potentially is a better marker for the diagnosis of OC and could be an important early indicator of the recurrence of the disease."

Announcement: Annual International Gathering - Ovarian Cancer/ACOR

ACOR

Further information/registration (free): http://www.ocats.ca

Abstract: Risk factors for epithelial ovarian cancer by tumor dominance, a surrogate for cell of origin -Cancer Prevention Research

"Although limited by small case numbers, our results suggest that tubal ligation may be more strongly associated with tumors of ovarian origin, while family history of ovarian cancer primarily increases risk of tumors of tubal origin. Characterizing risk factor relationships by tumor dominance may elucidate how these exposures alter risk and help to improve prevention efforts."

Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers-France

Note: ignore the small spelling errors in the article as it was translated from French to English

Fertility-sparing surgery in young women with invasive epithelial ovarian cancer.

Note: this study also discusses tumour rupture/survival; the abstract does not include specific cell types, however, clear cell can be possibly presumed given the research data on Japanese women with clear cell ovarian cancer.

Journal of Experimental & Clinical Cancer Research | Full text | Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research

Note: there is a specific section on ovarian cancer

Background: Viscum album L. extracts (VAE, European mistletoe) are a widely used medicinal plant extract in gynaecological and breast-cancer treatment.  Conclusion: VAE shows some positive effects in breast and gynaecological cancer. More research into clinical efficacy is warranted.

media article: The inherited malignancy of breast cancer (and ovarian cancer)

Note: good article, albeit complicated subject matter - excerpts of important information:

media article: Plant-based flavonoid may cut ovarian cancer risk (Apigenin)

language issues: borderline - significant ??

"women reporting the highest apigenin intake had a "borderline significant decrease" in ovarian cancer risk"

Cleaning service offers comfort to sick clients - STLtoday.com )St Louis)